Pimicotinib in patients with tenosynovial giant cell tumour (TGCT): 2-year analysis of the phase 3 MANEUVER trial

Gelderblom | 3747P

The impact of pimicotinib on quality of life (QoL) in patients with tenosynovial giant cell tumour (TGCT): EQ-5D-5L findings from the phase 3 MANEUVER trial

Razak | 3756P

Precemtabart tocentecan (Precem-TcT) in patients with metastatic colorectal cancer (mCRC): Updated survival data from the Phase 1 PROCEADE-CRC-01 study

Garcia-Carbonero | 824P

Patient characteristics and treatment patterns of patients (pts) with advanced NSCLC harboring MET exon 14 (METex14) skipping enrolled in MOMENT disease registry

Thomas | 2701P

Treatment (tx) rates and predictors of overall survival (OS) among patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): findings from a retrospective observational study in Sweden

Aly | 4796eP

Real-world effectiveness and safety of first-line (1L) avelumab in patients (pts) with stage III Merkel cell carcinoma (MCC): results from a prospective German registry (MCC-TRIM)

Becker | 2497P

Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC) in Europe and Russia: interim overall population and Spain subgroup analyses from the real-world AVENUE study

Diaz | 4782eP

Outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC) by NECTIN4 and ERBB2 amplification status: exploratory analyses from JAVELIN Bladder 100

Klümper | 4763P

Predictors of systemic anticancer therapy (SACT) receipt and survival outcomes in adults with locally advanced or metastatic urothelial carcinoma (la/mUC) in England

Stevenson | 4850eP